Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEVE-PEDS
2025-524811-35-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Orforglipron with Dulaglutide (2 arms). Primary endpoint: Change from baseline in hemoglobin A1c. Planned start Oct 2026; status: authorised.
02
Drugs
orforgliprondulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2025-524811-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524811-35-00.